May 22, 2019

The Role and Importance of HPV Infection
in Head and Neck Cancer

 

Trevor G. Hackman, MD, FACS

Trevor Hackman, MD, FACS

Vice Chair, Department of Otolaryngology/Head and Neck Surgery
Assistant Professor, Department of Otolaryngology/Head and Neck Surgery
Director, Head and Neck Oncology Fellowship
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill

Lecture Description

Dr. Trevor Hackman is the Director of the Head and Neck Oncology Fellowship and specializes in treatment of patients with diseases and disorders of the ear, nose, throat (ENT), with a focus in head and neck oncology. In this lecture, he will talk about the Human Papillomavirus (HPV) in head and neck cancers in terms of epidemiology, vaccination, molecular/genomics, de-escalation, role of TORS, and immunotherapy.

Lecture Objectives:
  • Describe the epidemiology of Human Papilloma Virus (HPV) infection
  • Identify the epidemiology of HPV-related head and neck cancer
  • Discuss the impacts of HPV on treatment and prognosis
  • Differentiate treatment options, areas of exploration & prevention

 


April 24, 2019

Improving Outcomes in Radical Cystectomy

 

Raj S. Pruthi, MD

Raj S. Pruthi, MD

Chair, Department of Urology
Professor, Urologic Oncology
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill

Lecture Description

The lecture will evaluate the recent improvements in patients undergoing radical cystectomy for bladder cancer (including peri-operative chemotherapy and robotic surgery) and will describe some of the obstacles to providing optimal care that still exist.

Lecture Objectives:
  • Recognize the advances in surgical treatment of invasive bladder
  • Understand obstacles to optimal outcomes in bladder cancer patients
  • Identify the advances in the peri-operative management of cystectomy patients

 


March 27, 2019

Immunological Mechanisms in Pancreatic Cancer

 

Yuliya Pylayeva-Gupta, PhD

Yuliya Pylayeva-Gupta, PhD

Assistant Professor
Department of Genetics
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill

Lecture Description

This lecture will review the current understanding of the role of immune system in pancreatic cancer and provide insight into development of the latest immune-based therapies aimed at treating patients with pancreatic cancer.

Lecture Objectives:
  • Describe the etiology and current treatment of pancreatic ductal adenocarcinoma.
  • Discuss the challenges imposed by tumor microenvironment in treating pancreatic cancer.
  • Discuss novel approaches to immunotherapy in pancreatic cancer.

 


February 27, 2019

Key 2018/2019 Developments
in Lymphoma and Thrombosis/Anticoagulation

 

Stephan Moll, MD

Stephan Moll, MD

Professor of Medicine
Hemophilia and Thrombosis Center
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill

Anne W. Beaven, MD

Anne W. Beaven, MD

Associate Professor of Medicine
Director, Lymphoma Program
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill

Lecture Description

Each year, the American Society of Hematology (ASH) hosts a conference highlighting some of the latest hematologic oncology research. Join us as our speakers highlight some of the top presentations on Non-Malignant Hematology and Lymphoma from this year’s ASH conference.
Dr. Beaven will present a concise review of the most relevant and practice changing lymphoma abstracts that were presented at the American Society of Hematology Annual Meeting in 2018.

Lecture Objectives:
  • Discuss the risk/benefit of prophylactic dose apixaban or rivaroxaban in ambulatory cancer patients starting chemotherapy, who have never had a DVT or PE.
  • Decide which anticoagulant is best to use in the severely obese patient and the patient who has had bariatric surgery who has an indication for full dose anticoagulation.
  • Describe the use of brentuximab vedotin as front line treatment of patients with CD30+ Peripheral T Cell Lymphoma.
  • Recognize that a short course of RCHOP chemotherapy alone may be effective in treatment of young patients with low risk DLBCL.

 


January 23, 2019

Best of ASH 2018: Myeloma and Leukemia/MDS

 

Brandi Reeves, MD

Brandi Reeves, MD

Professor of Medicine
Malignant Hematology
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill

Matthew Foster, MD

Matthew Foster, MD

Associate Professor, Clinical Research
Leukemia, Lymphoma, and Myeloma Program
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill

Lecture Description

Each year, the American Society of Hematology (ASH) hosts a conference highlighting some of the latest hematologic oncology research. Join us as our speakers discuss some of the top presentations on Myeloma and Leukemia/MDS from this year’s ASH conference.

Lecture Objectives:
  • Compare the outcomes of previously untreated patients with chronic lymphocytic leukemia (CLL) who are treated with ibrutinib versus those treated with chemo-therapy.
  • Describe which patients with myelodysplastic syndromes may benefit from treatment with luspatercept.
  • Identify appropriate patients with myelodysplastic syndromes for iron chelation with defarasirox and list adverse outcomes that may be prevented by using this agent.

 


December 19, 2018

An Update on CAR T Therapy

 

Natalie Grover, MD

Natalie Grover, MD

Assistant Professor
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill

Lecture Description

This lecture will give an overview of CAR-T cells, discuss recent clinical trial results and FDA approvals as well as current clinical applications. This lecture will also cover the management of the unique toxicities of CAR-T therapy. Finally, this lecture will discuss some of the ongoing trial of CAR-T therapy as well as future directions of the field.

Lecture Objectives:
  • Discuss the current approved indications for CAR-T cells.
  • Describe presentation and management of unique toxicities associated with CAR-T therapy.
  • Describe challenges of developing CAR-T cells for solid tumors.

 


November 28, 2018

Understanding and Treating Anxiety & Depression
in Patients and Families with Cancer

 

Eliza Park, MD

Eliza Park, MD

Assistant Professor, Department of Psychiatry
Clinical Assistant Professor, Clinical Research
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill

Lecture Description

Depression and anxiety disorders commonly occur among patients with cancer and their family caregivers. This lecture focuses on the common symptoms and management strategies for depression and anxiety disorders in patients with cancer and their family members.

Lecture Objectives:
  • Describe the epidemiology of depression and anxiety disorders in patients with cancer and their family caregivers.
  • Recognize the initial pharmacologic and non-pharmacologic treatment strategies for anxiety and depression in cancer.
  • Identify the major risk factors for suicide among patients with cancer.

 


October 24, 2018

Aerobic and Resistance Exercise in Cancer Patients:
Methods and Benefits

 

Claudio L. Battaglini, PhD, FACSM

Claudio L. Battaglini, PhD, FACSM

Professor, Cancer Prevention and Control
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill

Bill Wood, MD

Bill Wood, MD

Associate Professor, Clinical Research
Leukemia, Lymphoma, and Myeloma Program
Bone Marrow and Stem Cell Transplantation Program
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill

Lecture Description

In this presentation, Dr. Wood and Dr. Battaglini will review the importance of physical function (also referred to as physical performance) in patients receiving treatment for cancer, followed by a review of the mechanisms and evidence base supporting the role of exercise in improving cancer outcomes. Examples of aerobic and resistance exercise interventions will be discussed.

Lecture Objectives:
  • Discuss the relevance of physical performance in predicting outcomes and the patient experience in individuals who have received treatment for cancer.
  • Differentiate methods for measuring and modeling physical performance in cancer.
  • Describe the benefits that aerobic, resistance, and combined exercise interventions have upon physical performance and outcomes in cancer.

 


September 26, 2018

Tumor Treating Fields for Glioblastoma

 

Simon Khagi, MD

Simon Khagi, MD

Assistant Professor, Medicine and Neurosurgery
Director, UNC Brain Tumor Program
Department of Neurosurgery
UNC School of Medicine
University of North Carolina at Chapel Hill

Lecture Description

Glioblastoma is a devastating disease with a survival that is measured in months. The recent FDA approval of the Optune device for the treatment of newly-diagnosed glioblastoma was a paradigm shift in the field of neuro-oncology. We will focus our discussion on the biological underpinnings of this device and clinical data supporting its use.

Lecture Objectives:
  • Discuss the outcomes and treatment of glioblastoma before the introduction of Optune
  • Explain the mechanism of actions and early research that led to the approval of Optune by the FDA
  • Describe the evolving role of Optune in the management of glioblastoma

 


August 22, 2018

Recent Advances
on the Gut Microbiome and Cancer Therapy

 

 Temitope O. Keku, MSPH, PhD

Temitope O. Keku, MSPH, PhD

Associate Professor, Cancer Epidemiology
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill

Lecture Description

The gut microbiome is responsible for regulation of many functions in humans including metabolism, immune responses and inflammation. This lecture will focus on the gut microbiome and their interactions with the host to influence cancer treatment outcomes.

Lecture Objectives:
  • Describe the gut microbiome and how changes in composition influence health and disease
  • Understand how the gut microbiome interacts with the immune system to affect response to cancer therapy, especially immunotherapy
  • Future directions and strategies to manipulate the gut microbiome to improve clinical outcomes in cancer patients

 


July 25, 2018

Novel Molecularly Targeted Therapies
and Biomarkers in Advanced Colorectal Cancer

 

Michael Lee, MD

Michael Lee, MD

Assistant Professor, Molecular Therapeutics
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill

Lecture Description

Treatment of metastatic colorectal cancer has continued to evolve over the last several years, with emerging identification of biomarkers that underlie heterogeneity of responses to new and existing therapy. Ongoing clinical research seeks to identify new therapeutic options in molecularly-defined subgroups of patients. We will review the most exciting and clinically impactful research findings in this presentation.

Lecture Objectives:
  • Discuss important clinicopathologic features underlying the biology of colorectal cancer
  • Describe varying sequences of therapies in management of metastatic colorectal cancer
  • Describe biomarkers that guide selection and personalization of therapies for patients with advanced colorectal cancer

 


June 27, 2018

Using Biomarkers to Plan
Adjuvant Therapy in Breast Cancer

 

Lisa Carey, MD

Lisa Carey, MD

Richardson and Marilyn Jacobs Preyer Distinguished Professorship for Breast Cancer Research
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill

Lecture Description

Dr. Carey will discuss the anatomic and genomic variables that impact on (neo)adjuvant decision-making in breast cancer and the current treatment algorithms that allow rational escalation and de-escalation of systemic therapy.

Lecture Objectives:
  • Understand the roles of stage, hormone receptors, and biologic assays in determining systemic treatment and outcome.
  • Recognize the features that make a tumor more appropriate for neoadjuvant systemic therapy and the implications of this approach to therapy.
  • Determine the optimal regimens for triple negative, hormone receptor-positive, and HER2-positive breast cancer.

 


May 23, 2018

Acute Myeloid Leukemia (AML):
Finally Making Progress?

 

Joshua Zeidner, MD

Joshua Zeidner, MD

Assistant Professor
Clinical Research
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill

Lecture Description

Acute Myeloid Leukemia (AML) is an aggressive hematologic malignancy that affects approximately 20,000 patients each year in the United States. Management of AML has changed little over the last several decades and outcomes remain unsatisfactory. However, recent drug discoveries and approvals show tremendous promise. This presentation will review the current treatment armamentarium of AML highlighting novel concepts and investigational agents in development.

Lecture Objectives:
  • Discuss pathogenesis/etiology of AML
  • Identify diagnostic testing in AML
  • Discuss management of AML in younger and older patient populations in the context of recent drug approvals, highlighting some investigational agents in development

 


April 25, 2018

GU Cancers: Best of ASCO

 

Matthew Milowsky, MD

Matthew I. Milowsky, MD

Professor of Medicine
Clinical Professor, Urology
Section Chief, Genitourinary Oncology Service
Co-Director, Urologic Oncology Program
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill

Lecture Description

The Genitourinary Cancers Symposium co-sponsored by the American Society of Clinical Oncology (ASCO), American Society for Radiation Oncology (ASTRO), and Society of Urologic Oncology (SUO) provides some of the latest findings in genitourinary cancers (including prostate, bladder, kidney and testicular cancers). This lecture will highlight some of the cutting-edge research findings presented at the 2018 meeting.

Lecture Objectives:
  • Describe recent advances using antiandrogen therapy in patients with nonmetastatic castration-resistant prostate cancer.
  • Discuss the use of novel combination therapy approaches with immune checkpoint inhibitors in metastatic renal cell cancer.
  • Review the evolving landscape for immunotherapy in patients with advanced bladder cancer.

 


March 28, 2018

Meeting the Unique Needs
of Pediatric Oncology Patients

 

Thomas Alexander, MD, MPH

Thomas Alexander, MD, MPH

Assistant Professor, Department of Pediatrics
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill

Lecture Description

Children with cancer, and their clinicians, face a unique spectrum of challenges. Differences in diagnosis, biology, treatment toxicity, and impact on social development require focused teams of researchers, healthcare providers, psychologist, and social workers. Novel diagnostic and treatment paradigms require intricate systems for data interpretation and therapy delivery, but come with a hope of improved survival and quality of life.

Lecture Objectives:
  • Describe the epidemiology of childhood cancer and the growing number of survivors
  • List the challenges and opportunities facing clinicians (and children and families) during intensive multi-modal therapy
  • Discuss novel frontiers of precision medicine and immunotherapy in pediatric oncology

 


February 21, 2018

A New Era:
Immunotherapy in Non-Small Cell Lung Cancer

 

Chad Pecot, MD

Chad Pecot, MD

Assistant Professor
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill

Lecture Description

This lecture will describe the rationale behind using immunotherapy in lung cancer, the current standard of care use of immunotherapy, and future directions.

Lecture Objectives:
  • Describe basic tumor immunology and concepts regarding use of the immune system to combat cancer.
  • Identify current FDA approved immunotherapies in lung cancer.
  • Recognize promising future directions in immunotherapy.

 


January 24, 2018

Managing Lung Cancer Heterogeneity

 

Jason Akulian, MD, MPH

Jason Akulian, MD, MPH

Assistant Professor of Medicine
Director, Interventional Pulmonology
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill

Lecture Description

The most common lung cancers are known to have diverse pathological features and recent research has further identified distinct diseases with genetic and cellular heterogeneity. This lecture will provide strategies for managing this heterogeneity during clinical evaluation and treatment of patients.

Lecture Objectives:
  • Define lung cancer heterogeneity.
  • Discuss lung cancer heterogeneity.
  • Identify treatment decisions based on a patient’s lung cancer heterogeneity.